Michael Valastro, MD
Orthopaedic Surgery · Round Rock, TXNPI 1619081312
Payments from drug & device makers
Across 149 payments — averaging $137.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Therapeutics, Inc.$10K
- Smith+Nephew$5K
- Medinc Of Texas$2K
- Arthrex$2K
- Stryker$268
- Orthalign Inc$225
- plus $684 from 10 others
What the payments were for
- Speaking & faculty fees$8,45041%
- Travel & lodging$5,12725%
- Food & beverage$4,70123%
- Education$2,14511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Therapeutics, Inc. | 67 | $10,195 |
| Smith+Nephew | 32 | $4,833 |
| Medinc Of Texas | 3 | $2,275 |
| Arthrex | 16 | $1,941 |
| Stryker | 5 | $268 |
| Orthalign Inc | 4 | $225 |
| Heron Therapeutics, Inc. | 2 | $192 |
| Radius Health, Inc. | 1 | $123 |
| Bioventus LLC | 5 | $105 |
| Pacira Pharmaceuticals Incorporated | 3 | $65 |
| Ferring Pharmaceuticals Inc. | 4 | $60 |
| Abbott | 3 | $57 |
| Kerecis Limited | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Vertex | 1 | $19 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zilretta$9,712
- RI.HIP NAVIGATION$3,170
- JOURNEY$2,917
- OR3O Dual Mobility$2,040
- REAL INTELLIGENCE$1,833
- POLARSTEM$1,534
- Journey II$1,423
- Tandem$908
- VISIONAIRE Cutting Guides$364
- Journey II XR$364
- Anthology$252
- 1688$135
- ACCOLADE$135
- CROSSFIRE$135
- FORMULA$135
- Zynrelef$119
How this compares
$20,422 in reported general payments places this provider in the 75th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 266 | $2,856 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 103 | $1,394 |
| Celecoxib | 52 | $1,227 |
| Dexamethasone | 108 | $801 |
| Enoxaparin Sodium | 20 | $646 |
| Cephalexin | 58 | $144 |
| Tramadol Hcl | 31 | $119 |
| Methylprednisolone | 25 | $109 |
| Ibuprofen | 18 | $108 |
| Meloxicam | 46 | $101 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Round Rock
- Stephen BurkhartSan Antonio$185.3M
- Kirby HittTemple$9.1M
- J Richard EvansonPlano$8.1M
- Stefan KreuzerHouston$7M
- Robert GrahamAustin$6.3M
- Richard JonesDallas$6.3M
- Howard HarrisBedford$4.6M
- Tiffany HuynhHouston$4.6M
- Michael WirthSan Antonio$4.5M
- Stephen IncavoHouston$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.